SOL-GEL TECHNOLOGIES LTD
SLGLNASDAQTrading Snapshot
- Day Range
- $71.37 – $72.65
- 52-Week Range
- $27.00 – $97.97
- Volume
- $2.42B
- Avg Volume
- $1.90B
- Shares Outstanding
- 3.3M
- Next Earnings
- Oct 25, 2026
Fundamentals Snapshot
- Annual Revenue
- $19M
- Last Q Revenue
- $591,000
- P/E Ratio
- -11.9
- P/S Ratio
- 121.7x
- EPS (TTM)
- $-5.00
- Dividend Yield
- 0.00%
- Dilution (1yr)
- −90.0%
Why Investors Own SLGL
- ✓High-growth profile — revenue up +23.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
SOL-GEL TECHNOLOGIES LTD
SLGL
StockOtter · stockotter.spaceAbout SOL-GEL TECHNOLOGIES LTD
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation technology, with their primary development and commercialization activities centered in Israel. Sol-Gel's pipeline features several key candidates. Twyneo, an innovative, non-antibiotic topical cream designed for once-daily application, has successfully concluded Phase III trials for treating acne vulgaris. Similarly, Epsolay, another topical cream administered once a day, has also completed its Phase III studies, targeting papulopustular rosacea. Advancing through Phase I clinical trials is SGT-210, intended for palmoplantar keratoderma. Furthermore, the company is investigating Erlotinib, Tapinarof, and Roflumilast as potential treatments for psoriasis and various other medical conditions. Beyond its proprietary offerings, the company also engages in creating generic versions of topical dermatological medications. Sol-Gel Technologies maintains a strategic partnership with Perrigo. Established in 1997, the company maintains its headquarters in Ness Ziona, Israel.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Head-To-Head Review: Heron Therapeutics (NASDAQ:HRTX) vs. Sol-Gel Technologies (NASDAQ:SLGL)
Sol-Gel Technologies (NASDAQ: SLGL - Get Free Report) and Heron Therapeutics (NASDAQ: HRTX - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two business
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
SolGel Technologies (SLGL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street an
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
Last patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome Top-line results remain on track for late November 2026 NESS ZIONA, Israe
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
NESS ZIONA, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today announced financial r